Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Intangibles (2023 - 2024)

Historic Intangibles for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $2.1 million.

  • Zhengye Biotechnology Holding's Intangibles changed N/A to $2.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 7724.22% down from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Intangibles of $2.1 million as of Q2 2025.
  • Over the past 5 years, Zhengye Biotechnology Holding's Intangibles peaked at $8.9 million during Q4 2023, and registered a low of $2.1 million during Q4 2024.
  • Its 3-year average for Intangibles is $4.4 million, with a median of $2.1 million in 2025.
  • Examining YoY changes over the last 5 years, Zhengye Biotechnology Holding's Intangibles showed a top increase of 7680.62% in 2024 and a maximum decrease of 7680.62% in 2024.
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Intangibles stood at $8.9 million in 2023, then crashed by 76.81% to $2.1 million in 2024, then increased by 2.77% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q2 2025, $2.1 million for Q4 2024, and $8.9 million during Q4 2023.